Lucid Diagnostics Inc. (NASDAQ: LUCD) has announced an $18 million equity offering that will sell 18 million common shares at $1.00 per share. A $15 million anchor investment from a fundamental institutional investor underpins the deal, and the offering is expected to close on or about April 24, 2026. The transaction is being conducted under a shelf registration statement on Form S‑3, effective March 26, 2026, with Canaccord Genuity and BTIG serving as joint bookrunners.
Proceeds will be directed toward working capital and general corporate purposes, with a focus on accelerating the commercialization of the EsoGuard testing platform and pursuing Medicare coverage. The company has highlighted the importance of securing payer reimbursement as a catalyst for revenue growth, noting that Medicare coverage could unlock a payment rate of $1,938 per test against a cost of goods sold of $1,200.
Lucid Diagnostics reported Q4 2025 revenue of $1.5 million and a non‑GAAP adjusted loss of approximately $12.6 million, or $(0.10) per share. The company’s net loss for 2025 was $70.57 million, a 33.1% increase from 2024, and it posted negative free cash flow of $46.68 million over the last twelve months. With $34.7 million in cash and cash equivalents as of December 31, 2025, the equity raise is intended to extend the firm’s cash runway while it continues to invest in product development and payer negotiations.
Investors have expressed concern about the dilution impact of issuing 18 million new shares at $1.00 per share, a price below the company’s current trading level. The market reaction has been negative, reflecting the perceived risk that the offering could dilute existing shareholders and affect valuation.
CEO Lishan Aklog has emphasized confidence in obtaining Medicare coverage, stating that the company is “really confident that we are gonna get Medicare coverage not a matter of if but when.” He added that progress in the Medicare coverage process is in the late stages, underscoring the strategic importance of payer approval for the company’s long‑term revenue trajectory.
The capital infusion provides Lucid Diagnostics with additional liquidity to support its growth initiatives, including scaling the EsoGuard platform and expanding payer coverage. While the dilution risk remains a concern for investors, the funding is expected to strengthen the company’s financial position and accelerate the commercialization of its flagship product, positioning it for future revenue expansion once Medicare and other payer coverage are secured.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.